Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 801 results for "eisai"

Eisai Inc. (ESALF.PK) Release: LENVIMA (lenvatinib) Now Available Through Two Specialty Pharmacies, Accredo And Biologics, Inc. 2/27/2015
ClinicSpace

Eisai Inc. (ESALF.PK) Release: LENVIMA (lenvatinib) Now Availa...

WOODCLIFF LAKE, N.J. , Feb. 27, 2015 /PRNewswire/ --Eisai Inc. announced today that LENVIMA (lenvatinib), a receptor tyrosine kinase inhibitor, is now available through two specialty pharmacies, Accredo and Biologics, Inc. LENVIMA is indicated for ... ClinicSpace, 7 hours ago
[x]  

34 images for eisai

BioSpace, 6 hours ago
Pharmafocus, 1 day ago
Monthly Prescribing Reference, 2 days ago
Pharmaceutical Journal, 1 week ago
Seeking Alpha, 3 days ago
Asian Scientist, 1 week ago
Pharma Letter, 2 weeks ago
Pharmafocus, 1 week ago
Pharmaceutical Manufacturing Magazine, 1 week ago
Pharmaceutical Manufacturing Magazine, 1 week ago

Phase III Trial of Anticancer Agent Halaven(R) (eribulin) in Soft Tissue Sarcoma Shows Overall Survival Benefit in Primary Endpoint

/PRNewswire/ -- Eisai demonstrates commitment to rare cancers Eisai announces today that in the Phase III trial (Study 309) of Halaven(R) (eribulin) in patients with soft tissue sarcoma, eribulin demonstrates a statistically significant ...
 Individual.com3 days ago EISAI : to Establish Oral Solid Dose Production Facility at New Suzhou Plant in China  4 Traders2 days ago EISAI : Additional Exploratory Analysis of Phase II Trial Suggests Anticancer Agent Lenvatinib Extends Overall Survival in Patients with Advanced Non-small Cell Lung Cancer  4 Traders3 days ago Eisai Launches Proton Pump Inhibitor Pariet Tablets 5 Mg In Japan  FirstWord Pharma3 days ago
[x]  
Seeking Alpha

Arena: Belviq Television Ads Resume After 1 Week Hiatus

Feb. 24, 2015 8:11 AM ET | About: Arena Pharmaceuticals, Inc. (ARNA), Includes: OREX by: Spencer Osborne Summary Eisai identified low price and television ads as new strategy. Televion ad numbers have declined throughout 2015. In its most ...
 Seeking Alpha3 days ago Arena's Belviq Prescriptions Hold Up During Presidents' Day Holiday Week  Seeking Alpha4 hours ago Arena's Belviq Scripts Spike - Maintaining This Trajectory Important  Seeking Alpha1 week ago Arena's Belviq Hits New High Prescription Mark, But Needs Similar Future Growth  Seeking Alpha1 week ago

Eisai's Phase I/II renal cell carcinoma trial meets primary endpoint

Eisai Co., Ltd., a Japanese pharmaceutical company, has announced that the second part of its Phase I/II clinical trial, or study 205, with an in-house developed anticancer agent, lenvatinib mesylate, in patients with unresectable advanced or ...
 Individual.com1 week ago Eisai provides annual outlook  Individual.com1 week ago

Japan Pharmaceuticals and Healthcare Report Q2 2015

FEATURED COMPANIES Astellas AstraZeneca Daiichi Sankyo Eisai GlaxoSmithKline Merck & Co MORE Japan's healthcare system will come under increasing financial strain due to ...
 Research and Markets3 days ago Japan's Eisai Co., Ltd (ADR) Gets US FDA Green Signal For Thyroid Cancer Drug  Bidness Etc1 week ago

Eisai's Epilepsy Treatment Zonegran(R) (Zonisamide) Approved for Use in Children and Adolescents in France

/PRNewswire/ -- PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS On the 9 February, the Transparency Commission of the French National Authority for Health (HAS) published its advice on Zonegran(R) (zonisamide) in its new ...
 Individual.com1 week ago ZONEGRAN® (ZONISAMIDE), traitement de l'épilepsie des laboratoires EISAI, autorisé en France chez l'enfant et l'adolescent  BioMedReports1 week ago
[x]  

US FDA approves Eisai's antiepileptic drug Banzel as adjunctive treatment for paediatric patients

The US Food and Drug Administration (FDA) has granted an additional paediatric indication approval for Eisai Inc's antiepileptic drug (AED) Banzel (rufinamide). Through this approval, Banzel, which had been approved for the adjunctive treatment of ...
 PharmaBiz1 week ago FDA grants expanded approval for Eisai's antiepileptic drug Banzel for pediatric patients [EMBIN (Emerging Markets Business Information News]  Pharmacy Choice1 week ago Eisai : FDA grants expanded approval for Eisai's antiepileptic drug Banzel for pediatric patients  4 Traders1 week ago

Painting contest held

A painting competition for students of Zilla Parishad High School, Lemerti, was conducted by Eisai on Friday on the theme Safety Health Environment. The competition will be held at
 The Hindu2 weeks ago
Pharmafocus

Eisai cancer drug performs in sarcoma disease

Eisai's cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in a recent Phase III clinical trial. The Japanese company's injectable non-taxane, microtubule dynamics inhibitor ...
 Pharmafocus1 day ago Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object  Fierce CRO1 week ago Eisai wins an early FDA nod for its self-described cancer blockbuster  FierceBiotech2 weeks ago Eisai Expects Strong Sales From New Cancer Drug  Austin American Statesman2 weeks ago

Lenvatinib Approved for Advanced Thyroid Cancer

- FDA and Eisai Inc. on February 13 announced the approval of lenvatinib for the treatment of advanced thyroid cancer. Eisai, which will market the kinase inhibitor as Lenvima, stated that the product will be available to order "in the near ...
 Noodls1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less